Mirum Pharmaceuticals, Inc. (MIRM): R&D Expense
$186.18M
Year ended 2025-12-31
+20.3%
3-year compound annual growth
+17.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $186.18M | +32.4% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $140.63M | +37.1% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $102.61M | -4.0% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $106.84M | -18.7% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $131.43M | +61.1% | 2024-03-15, From 2021-01-01 |
| 2020-12-31 | $81.61M | +89.8% | 2022-03-09, From 2020-01-01 |
| 2019-12-31 | $42.99M | n/a | 2021-03-09, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $186.18M | +32.4% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $451.95M | -10.8% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $148.29M | -30.1% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $206.01M | -5.3% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $44.54M | -11.4% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $220.90M | -5.8% |
| Insmed Inc (INSM) | 2025-12-31 | $771.09M | +28.9% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $124.03M | +17.9% |
Compare MIRM, BBIO, HCM, TVTX side by side · Screen every company in Pharmaceutical Preparations ↗